These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 31289117)
1. A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer. Hüttenhain R; Choi M; Martin de la Fuente L; Oehl K; Chang CY; Zimmermann AK; Malander S; Olsson H; Surinova S; Clough T; Heinzelmann-Schwarz V; Wild PJ; Dinulescu DM; Niméus E; Vitek O; Aebersold R Mol Cell Proteomics; 2019 Sep; 18(9):1836-1850. PubMed ID: 31289117 [TBL] [Abstract][Full Text] [Related]
2. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402 [TBL] [Abstract][Full Text] [Related]
3. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433 [TBL] [Abstract][Full Text] [Related]
4. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095 [TBL] [Abstract][Full Text] [Related]
5. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling. Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595 [TBL] [Abstract][Full Text] [Related]
6. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers]. Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789 [TBL] [Abstract][Full Text] [Related]
7. Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis. Mansha M; Gill A; Thomson PC Mol Biol Rep; 2019 Jun; 46(3):3325-3332. PubMed ID: 31006098 [TBL] [Abstract][Full Text] [Related]
8. A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium. Pils D; Tong D; Hager G; Obermayr E; Aust S; Heinze G; Kohl M; Schuster E; Wolf A; Sehouli J; Braicu I; Vergote I; Van Gorp T; Mahner S; Concin N; Speiser P; Zeillinger R BMC Cancer; 2013 Apr; 13():178. PubMed ID: 23551967 [TBL] [Abstract][Full Text] [Related]
9. Developing a mass spectrometry-based assay for the ovarian cancer biomarker CA125 (MUC16) using suspension trapping (STrap). Schuster-Little N; Madera S; Whelan R Anal Bioanal Chem; 2020 Sep; 412(24):6361-6370. PubMed ID: 32215689 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer. Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570 [TBL] [Abstract][Full Text] [Related]
11. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214 [TBL] [Abstract][Full Text] [Related]
12. New tumor markers: CA125 and beyond. Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244 [TBL] [Abstract][Full Text] [Related]
14. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages. Wang Z; Tao X; Ying C Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130 [TBL] [Abstract][Full Text] [Related]
15. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Ye B; Cramer DW; Skates SJ; Gygi SP; Pratomo V; Fu L; Horick NK; Licklider LJ; Schorge JO; Berkowitz RS; Mok SC Clin Cancer Res; 2003 Aug; 9(8):2904-11. PubMed ID: 12912935 [TBL] [Abstract][Full Text] [Related]
16. Selection of small plasma peptides for the auxiliary diagnosis and prognosis of epithelial ovarian cancer by using UPLC/MS-based nontargeted and targeted analyses. Lu X; Li Y; Xia B; Bai Y; Zhang K; Zhang X; Xie H; Sun F; Hou Y; Li K Int J Cancer; 2019 Apr; 144(8):2033-2042. PubMed ID: 30114318 [TBL] [Abstract][Full Text] [Related]
18. Development of a Chip/Chip/SRM platform using digital chip isoelectric focusing and LC-Chip mass spectrometry for enrichment and quantitation of low abundance protein biomarkers in human plasma. Rafalko A; Dai S; Hancock WS; Karger BL; Hincapie M J Proteome Res; 2012 Feb; 11(2):808-17. PubMed ID: 22098410 [TBL] [Abstract][Full Text] [Related]
19. Identification and validation of differential plasma proteins levels in epithelial ovarian cancer. Periyasamy A; Gopisetty G; Subramanium MJ; Velusamy S; Rajkumar T J Proteomics; 2020 Aug; 226():103893. PubMed ID: 32634479 [TBL] [Abstract][Full Text] [Related]
20. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs). Pearl ML; Dong H; Tulley S; Zhao Q; Golightly M; Zucker S; Chen WT Gynecol Oncol; 2015 May; 137(2):229-38. PubMed ID: 25769657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]